Sagimet Biosciences Reports Q3 2026 Loss of $0.27 Per Share, Missing Analyst Estimates
Clinical-stage biopharma funds operations through mid-2029 with $115 million October offering Related Stocks: SGMT ,
Clinical-stage biopharma funds operations through mid-2029 with $115 million October offering Related Stocks: SGMT ,